Page 65 - 南京医科大学自然版

第45卷第2期 蔡清清，尤含笑，王 磊，等. NLR和SII对抗MDA5抗体阳性皮肌炎伴快速进展型肺炎的预后价值［J］.
2025年2月 南京医科大学学报（自然科学版），2025，45（2）：196-207 ·205 ·

ing large⁃scale，multicenter，prospective studies to ex⁃ panding the clinical spectrum in North American patients
plore the application value of NLR and SII in anti ⁃ with dermatomyositis［J］. J Rheumatol，2017，44（3）：
+
MDA5 DM patients. 319-325
Availability of data and materials： ［7］ MOTEGI S I，SEKIGUCHI A，TOKI S，et al. Clinical fea⁃
tures and poor prognostic factors of anti⁃melanoma differ⁃
The datasets used during the current study are available
entiation⁃associated gene 5 antibody⁃positive dermatomyo⁃
from the corresponding author upon reasonable request.
Conflict of Interests： sitis with rapid progressive interstitial lung disease［J］.
Eur J Dermatol，2019，29（5）：511-517
The authors declare that they have no competing interest.
Author’s Contributions： ［8］ ZUO Y，YE L F，CHEN F，et al. Different multivariable
risk factors for rapid progressive interstitial lung disease
TAN Wengfeng designed the study. CAI Qingqing contrib⁃
in anti⁃MDA5 positive dermatomyositis and anti⁃synthe⁃
uted to the study design. YOU Hanxiao，LÜ Chengyin，WANG
tase syndrome［J］. Front Immunol，2022，13：845988
Lei，QIU Yulu，and SHI Yumeng recruited patients and ob⁃
［9］ ZHU Y J，WANG L，SUN Y K，et al. Serum Krebs von
tained consent for the study. CAI Qingqing and WU Lingyun an⁃
alyzed and interpreted the data. CAI Qingqing，WANG Fang， den Lungen⁃6 concentrations reflect severity of anti⁃mela⁃
noma differentiation ⁃ associated protein 5 antibody posi⁃
ZHANG Miaojia，and TAN Wenfeng wrote the manuscript. All
tive dermatomyositis associated interstitial lung disease［J］.
authors read，revised，and approved the final version of the man⁃
Clin Exp Rheumatol，2022，40（2）：292-297
uscript.
［10］SO J，SO H，WONG V T，et al. Predictors of rapidly pro⁃
Acknowledgements：
gressive interstitial lung disease and mortality in patients
We thank all authors for their continuous and excellent sup⁃
with autoantibodies against melanoma differentiation⁃asso⁃
port with patients’data collection，data analysis，statistical anal⁃
ciated protein 5 dermatomyositis［J］. Rheumatology，
ysis，and valuable suggestions for the article. Thanks to Dr.
2022，61（11）：4437-4444
SHEN Sipeng and Dr. LI Hongru，School of Public Health，Nan⁃
［11］XU A T，YE Y，FU Q，et al. Prognostic values of anti ⁃
jing Medical University for their help in statistics.
Ro52 antibodies in anti⁃MDA5⁃positive clinically amyo⁃
［参考文献］
pathic dermatomyositis associated with interstitial lung
［1］ WU W L，GUO L，FU Y K，et al. Interstitial lung disease disease［J］. Rheumatology，2021，60（7）：3343-3351
in anti⁃MDA5 positive dermatomyositis［J］. Clin Rev Al⁃ ［12］YAN D，DAI C J，XU R T，et al. Predictive ability of sys⁃
lergy Immunol，2021，60（2）：293-304 temic inflammation response index for the risk of pneumo⁃
［2］ SELVA ⁃ O’CALLAGHAN A，ROMERO ⁃ BUENO F， nia in patients with acute ischemic stroke［J］. Gerontolo⁃
TRALLERO ⁃ ARAGUÁS E，et al. Pharmacologic treat⁃ gy，2023，69（2）：181-188
ment of anti ⁃ MDA5 rapidly progressive interstitial lung ［13］BUONACERA A，STANCANELLI B，COLACI M，et al.
disease［J］. Curr Treat Options Rheum，2021，7（4）：319- Neutrophil to lymphocyte ratio：an emerging marker of the
333 relationships between the immune system and diseases［J］.
［3］ LIAN X Y，ZOU J，GUO Q，et al. Mortality risk prediction Int J Mol Sci，2022，23（7）：3636
in amyopathic dermatomyositis associated with interstitial ［14］LIU T，LI W，ZHANG Z H，et al. Neutrophil⁃to⁃lympho⁃
lung disease：the FLAIR model［J］. Chest，2020，158（4）： cyte ratio is a predictive marker for anti⁃MDA5 positive

1535-1545 dermatomyositis［J］. BMC Pulm Med，2022，22（1）：316
［4］ HUANG K，VINIK O，SHOJANIA K，et al. Clinical spec⁃ ［15］DONG F，ZHENG L T，AN W W，et al. A meta⁃analysis of
trum and therapeutics in Canadian patients with anti⁃mel⁃ the clinical significance of neutrophil⁃to⁃lymphocyte ra⁃
anoma differentiation⁃associated gene 5（MDA5）⁃positive tios in interstitial lung disease［J］. PLoS One，2023，18
dermatomyositis：a case⁃based review［J］. Rheumatol Int， （6）：e0286956
2019，39（11）：1971-1981 ［16］MIKOLASCH T A，GEORGE P M，SAHOTA J，et al. Multi
［5］ KOGA T，FUJIKAWA K，HORAI Y，et al. The diagnostic ⁃center evaluation of baseline neutrophil⁃to⁃lymphocyte
utility of anti⁃melanoma differentiation⁃associated gene 5 （NLR）ratio as an independent predictor of mortality and
antibody testing for predicting the prognosis of Japanese clinical risk stratifier in idiopathic pulmonary fibrosis［J］.
patients with DM［J］. Rheumatology，2012，51（7）：1278- EClinicalMedicine，2023，55：101758
1284 ［17］CHEN Y R，CAI J Y，ZHANG M M，et al. Prognostic role
［6］ MOGHADAM⁃KIA S，ODDIS C V，SATO S，et al. Anti⁃ of NLR，PLR and MHR in patients with idiopathic pulmo⁃
melanoma differentiation⁃associated gene 5 antibody：ex⁃ nary fibrosis［J］. Front Immunol，2022，13：882217